A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1 Antitryp

Project Details

StatusFinished
Effective start/end date11/10/2131/10/23

Funding

  • IQVIA RDS Pty. Limited: A$112,776.00